The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

l-Thalidomide     2-[(3S)-2,6-dioxo-3- piperidyl]isoindole-1...

Synonyms: Lopac-T-144, Tocris-0652, CHEMBL426123, SureCN455269, CHEBI:61918, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lopac-T-144


Psychiatry related information on Lopac-T-144


High impact information on Lopac-T-144


Chemical compound and disease context of Lopac-T-144


Biological context of Lopac-T-144


Anatomical context of Lopac-T-144


Associations of Lopac-T-144 with other chemical compounds


Gene context of Lopac-T-144

  • Thalidomide is a first-generation immuno-modulating agent that down-regulates TNF-alpha and VEGF [30].
  • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha [31].
  • CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production [32].
  • Thalidomide abolished the NF-kappaB-dependent reporter gene expression activated by overexpression of TNFR1, TNFR-associated factor-2, and NF-kappaB-inducing kinase, but not that activated by the p65 subunit of NF-kappaB [33].
  • Consistent with the observed inhibition of NF-kappaB, thalidomide blocked the cytokine-induced expression of NF-kappaB-regulated genes such as those encoding interleukin-8, TRAF1, and c-IAP2 [34].

Analytical, diagnostic and therapeutic context of Lopac-T-144


  1. Thalidomide in multiple myeloma. Kishi, Y., Oki, Y., Machida, U. N. Engl. J. Med. (2000) [Pubmed]
  2. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Jacobson, J.M., Greenspan, J.S., Spritzler, J., Ketter, N., Fahey, J.L., Jackson, J.B., Fox, L., Chernoff, M., Wu, A.W., MacPhail, L.A., Vasquez, G.J., Wohl, D.A. N. Engl. J. Med. (1997) [Pubmed]
  3. Thalidomide for the treatment of chronic graft-versus-host disease. Vogelsang, G.B., Farmer, E.R., Hess, A.D., Altamonte, V., Beschorner, W.E., Jabs, D.A., Corio, R.L., Levin, L.S., Colvin, O.M., Wingard, J.R. N. Engl. J. Med. (1992) [Pubmed]
  4. Thalidomide, immune modulation and narcolepsy. Kanbayashi, T., Nishino, S., Tafti, M., Hishikawa, Y., Dement, W.C., Mignot, E. Sleep. (1996) [Pubmed]
  5. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Potenza, L., Luppi, M., Morselli, M., Saviola, A., Ferrari, A., Riva, G., Longo, G., Marietta, M., Torelli, G. Thromb. Haemost. (2004) [Pubmed]
  6. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M.M., Pyle, L., Johnston, S.R., Ahern, R., Smith, I.E., Gore, M.E. Br. J. Cancer (2000) [Pubmed]
  7. Effects of thalidomide and pentobarbital on neuronal activity in the preoptic area during sleep and wakefulness in the cat. Kaitin, K.I. Psychopharmacology (Berl.) (1985) [Pubmed]
  8. The way towards adverse event monitoring in clinical trials. Wallander, M.A. Drug safety : an international journal of medical toxicology and drug experience. (1993) [Pubmed]
  9. Deep venous thrombosis and thalidomide therapy for multiple myeloma. Osman, K., Comenzo, R., Rajkumar, S.V. N. Engl. J. Med. (2001) [Pubmed]
  10. Thalidomide for malignant melanoma. Kudva, G.C., Collins, B.T., Dunphy, F.R. N. Engl. J. Med. (2001) [Pubmed]
  11. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. Rajkumar, S.V., Gertz, M.A., Witzig, T.E. N. Engl. J. Med. (2000) [Pubmed]
  12. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., Barlogie, B. N. Engl. J. Med. (1999) [Pubmed]
  13. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B., Merlini, G. Blood (2005) [Pubmed]
  14. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N.C., Stirling, D.I., Antin, J.H., Anderson, K.C. Blood (2004) [Pubmed]
  15. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N., Gillmore, J.D. Blood (2007) [Pubmed]
  16. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Offidani, M., Corvatta, L., Piersantelli, M.N., Visani, G., Alesiani, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., Ferranti, M., Rupoli, S., Scortechini, A.R., Giuliodori, L., Candela, M., Capelli, D., Montanari, M., Olivieri, A., Poloni, A., Polloni, C., Marconi, M., Leoni, P. Blood (2006) [Pubmed]
  17. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schroeder, G., Reeder, T., Zeldis, J.B., Tefferi, A. Blood (2003) [Pubmed]
  18. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Parman, T., Wiley, M.J., Wells, P.G. Nat. Med. (1999) [Pubmed]
  19. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G. J. Exp. Med. (1993) [Pubmed]
  20. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Makonkawkeyoon, S., Limson-Pobre, R.N., Moreira, A.L., Schauf, V., Kaplan, G. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  21. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Mileshkin, L., Biagi, J.J., Mitchell, P., Underhill, C., Grigg, A., Bell, R., McKendrick, J., Briggs, P., Seymour, J.F., Lillie, K., Smith, J.G., Zeldis, J.B., Prince, H.M. Blood (2003) [Pubmed]
  22. Endothelial cells in the bone marrow of patients with multiple myeloma. Vacca, A., Ria, R., Semeraro, F., Merchionne, F., Coluccia, M., Boccarelli, A., Scavelli, C., Nico, B., Gernone, A., Battelli, F., Tabilio, A., Guidolin, D., Petrucci, M.T., Ribatti, D., Dammacco, F. Blood (2003) [Pubmed]
  23. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Haslett, P.A., Corral, L.G., Albert, M., Kaplan, G. J. Exp. Med. (1998) [Pubmed]
  24. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. J. Exp. Med. (1991) [Pubmed]
  25. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. Joseph, I.B., Isaacs, J.T. J. Natl. Cancer Inst. (1998) [Pubmed]
  26. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Gordon, G.B., Spielberg, S.P., Blake, D.A., Balasubramanian, V. Proc. Natl. Acad. Sci. U.S.A. (1981) [Pubmed]
  27. Optimizing anti-TNF treatment in inflammatory bowel disease. Rutgeerts, P., Van Assche, G., Vermeire, S. Gastroenterology (2004) [Pubmed]
  28. Thalidomide: a novel therapy for microsporidiosis. Sharpstone, D., Rowbottom, A., Francis, N., Tovey, G., Ellis, D., Barrett, M., Gazzard, B. Gastroenterology (1997) [Pubmed]
  29. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A., Anderson, K.C. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  30. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Chanan-Khan, A., Miller, K.C., Takeshita, K., Koryzna, A., Donohue, K., Bernstein, Z.P., Mohr, A., Klippenstein, D., Wallace, P., Zeldis, J.B., Berger, C., Czuczman, M.S. Blood (2005) [Pubmed]
  31. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Stirling, D.I., Kaplan, G. J. Immunol. (1999) [Pubmed]
  32. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. Marriott, J.B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M.G., Stirling, D., Dalgleish, A.G. J. Immunol. (1998) [Pubmed]
  33. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. Majumdar, S., Lamothe, B., Aggarwal, B.B. J. Immunol. (2002) [Pubmed]
  34. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. Keifer, J.A., Guttridge, D.C., Ashburner, B.P., Baldwin, A.S. J. Biol. Chem. (2001) [Pubmed]
  35. Thalidomide for graft-versus-host disease after bone marrow transplantation. Saurat, J.H., Camenzind, M., Helg, C., Chapuis, B. Lancet (1988) [Pubmed]
  36. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Vasiliauskas, E.A., Kam, L.Y., Abreu-Martin, M.T., Hassard, P.V., Papadakis, K.A., Yang, H., Zeldis, J.B., Targan, S.R. Gastroenterology (1999) [Pubmed]
  37. Intractable insomnia after cessation of treatment with thalidomide. Fox, M.R., Harris, A. Gastroenterology (2001) [Pubmed]
WikiGenes - Universities